Literature DB >> 11120829

Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors.

W J Magner1, A L Kazim, C Stewart, M A Romano, G Catalano, C Grande, N Keiser, F Santaniello, T B Tomasi.   

Abstract

Epigenetic mechanisms are involved in regulating chromatin structure and gene expression through repression. In this study, we show that histone deacetylase inhibitors (DAIs) that alter the acetylation of histones in chromatin enhance the expression of several genes on tumor cells including: MHC class I, II, and the costimulatory molecule CD40. Enhanced transcription results in a significant increase in protein expression on the tumor cell surface, and expression can be elicited on some tumors that are unresponsive to IFN-gamma. The magnitude of induction of these genes cannot be explained by the effect of DAIs on the cell cycle or enhanced apoptosis. Induction of class II genes by DAIs was accompanied by activation of a repressed class II transactivator gene in a plasma cell tumor but, in several other tumor cell lines, class II was induced in the apparent absence of class II transactivator transcripts. These findings also suggest that the abnormalities observed in some tumors in the expression of genes critical to tumor immunity may result from epigenetic alterations in chromatin and gene regulation in addition to well-established mutational mechanisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120829     DOI: 10.4049/jimmunol.165.12.7017

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  114 in total

1.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

2.  Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.

Authors:  Dennis O Adeegbe; Yan Liu; Patrick H Lizotte; Yusuke Kamihara; Amir R Aref; Christina Almonte; Ruben Dries; Yuyang Li; Shengwu Liu; Xiaoen Wang; Tiquella Warner-Hatten; Jessica Castrillon; Guo-Cheng Yuan; Neermala Poudel-Neupane; Haikuo Zhang; Jennifer L Guerriero; Shiwei Han; Mark M Awad; David A Barbie; Jerome Ritz; Simon S Jones; Peter S Hammerman; James Bradner; Steven N Quayle; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2017-04-13       Impact factor: 39.397

3.  Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.

Authors:  Xiaoguang Wang; Brittany C Waschke; Rachel A Woolaver; Zhangguo Chen; Gan Zhang; Anthony D Piscopio; Xuedong Liu; Jing H Wang
Journal:  Cancer Immunol Res       Date:  2019-06-24       Impact factor: 11.151

4.  MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components.

Authors:  Ananthi J Asirvatham; Christopher J Gregorie; Zihua Hu; William J Magner; Thomas B Tomasi
Journal:  Mol Immunol       Date:  2007-12-03       Impact factor: 4.407

5.  Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP.

Authors:  Meghan Bushway; Kelly A Cycon; Kathleen Mulvaney; Shawn P Murphy
Journal:  Immunogenetics       Date:  2009-12-19       Impact factor: 2.846

6.  Entinostat: a promising treatment option for patients with advanced breast cancer.

Authors:  Roisin M Connolly; Michelle A Rudek; Richard Piekarz
Journal:  Future Oncol       Date:  2017-03-09       Impact factor: 3.404

Review 7.  MHC class II regulation by epigenetic agents and microRNAs.

Authors:  Thomas B Tomasi; William J Magner; Jennifer L Wiesen; Julian Z Oshlag; Felicia Cao; Alex N Pontikos; Christopher J Gregorie
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

8.  Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

Authors:  Pavan Reddy; Yaping Sun; Tomomi Toubai; Raimon Duran-Struuck; Shawn G Clouthier; Elizabeth Weisiger; Yoshinobu Maeda; Isao Tawara; Oleg Krijanovski; Erin Gatza; Chen Liu; Chelsea Malter; Paolo Mascagni; Charles A Dinarello; James L M Ferrara
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

Review 9.  Epigenetic mechanisms of tumor resistance to immunotherapy.

Authors:  Natalia Arenas-Ramirez; Dilara Sahin; Onur Boyman
Journal:  Cell Mol Life Sci       Date:  2018-08-23       Impact factor: 9.261

10.  Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.

Authors:  Bérengère Vire; Stéphane de Walque; Audrey Restouin; Daniel Olive; Carine Van Lint; Yves Collette
Journal:  PLoS One       Date:  2009-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.